Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease
Heike Rau-Berger1, Harald Mitfessel2, Thomas Glaab1
1Medical Affairs Germany, Respiratory Medicine, Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim; 2Pulmonology Practice, Remscheid, Germany
Aim: This observational study with tiotropium Respimat® was performed in a real-life setting to investigate its effectiveness with regard to physical functioning and tolerability.
Methods: Patients with chronic obstructive pulmonary disease (COPD; n = 1,230; mean age, 65.5 years) received tiotropium 5 µg once daily via Respimat® Soft Inhaler for 6 weeks in an open-label observational study. At baseline and week 6, patients completed the Physical Function subdomain [PF-10] of the Short Form (SF) 36 questionnaire.
Results: Improvement in standardized PF-10 score of ≥10 points was achieved by 61.5% of patients. Mean (SD) standardized PF-10 scores improved by 13.4 (15.9) points, from 49.0 (24.5) to 62.3 points (23.5; P < 0.001). Results in smokers (n = 435) were not significantly different to those in nonsmokers. The general condition of patients improved during treatment. Adverse events were reported by 4.0% of patients and were chiefly respiratory symptoms and dry mouth.
Conclusion: In COPD patients receiving tiotropium Respimat® in daily practice, physical function improved rapidly within 6 weeks of treatment, irrespective of smoking status.
Keywords: COPD, tiotropium, physical function, therapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]
Readers of this article also read:
Degradability, bioactivity, and osteogenesis of biocomposite scaffolds of lithium-containing mesoporous bioglass and mPEG-PLGA-b-PLL copolymer
Cai Y, Guo L, Shen H, An X, Jian H, Ji F, Niu Y
Published Date: 24 June 2015
Lee JY, Kim JS, Cho HJ, Kim DD
Published Date: 3 June 2014
Suzaki I, Asano K, Shikama Y, Hamasaki T, Kanei A, Suzaki H
Published Date: 6 September 2011
Amir Sharafkhaneh, Amarbir S Mattewal, Vinu M Abraham, et al
Published Date: 4 October 2010
Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease
Davood Attaran, Shahrzad M Lari, Mohammad Towhidi, et al
Published Date: 30 September 2010
Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
Beatrix Balint, Henrik Watz, Carolynn Amos, et al
Published Date: 6 September 2010
Pulmonary function tests, sputum induction, and bronchial provocation tests: diagnostic tools in the challenge of distinguishing asthma and COPD phenotypes in clinical practice
Efrossini Dima, Nikoletta Rovina, Christina Gerassimou, et al.
Published Date: 2 September 2010
Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters
L Pekka Malmberg, Paula Rytilä, Pertti Happonen, et al
Published Date: 4 August 2010
Donald P Tashkin
Published Date: 18 February 2010
Phakic anterior chamber intraocular lens (Verisyse™) implantation in children for treatment of severe ansiometropia myopia and amblyopia: Six-month pilot clincial trial and review of literature
Amir Pirouzian, Kenneth C Ip, Henry S O’Halloran
Published Date: 18 June 2009